Sinclair IS Pharma plc Acquires Atlean® from GSK Stiefel
Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair" or "the Group"), the international specialty pharmaceutical company, announces that it has acquired Atlean®, a dermal filler, from Stiefel the dermatology business of GSK for an undisclosed cash consideration. Atlean® combines a collagen stimulator and hyaluronic acid filler particularly for the treatment of the lower face and complements Sinclair's existing facial aesthetic brands, Sculptra® and Perfectha®. This acquisition enables Sinclair to add a collagen stimulator to market alongside Perfectha® in its international facial aesthetics business focused on Asia-Pacific, LATAM and Russia. In Europe Atlean® will provide Sinclair's aesthetic sales forces with a yet more comprehensive product range.
Atlean® has not been actively marketed in Europe since 2012 and requires the European CE Mark registration to be regained which is expected to take around 9-12 months. First revenues are therefore expected in H2 FY2015.